{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-061836","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.248636+00:00","generated_at":"2026-05-23T00:09:35.523196+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.73,"calibrated_materiality_score":0.73,"confidence":"high","headline":"Kura Oncology Q1 net loss $57.4M; NDA submitted for ziftomenib, $45M milestone earned","bullets":["NDA for ziftomenib in R/R NPM1-mutant AML submitted March 31, 2025; FDA review period expected Q2 2025.","Earned $45 million milestone from Kyowa Kirin for NDA submission; pro forma cash $703.2M.","Q1 collaboration revenue $14.1M (vs $0 in Q1 2024); R&D expenses $56.0M, up 54% YoY.","Cash, equivalents and short-term investments $658.2M at March 31, 2025; runway into 2027.","First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST; data at ASCO and EHA upcoming."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-061836","json":"https://secwatch.observer/filing/0000950170-25-061836.json","markdown":"https://secwatch.observer/filing/0000950170-25-061836.md","text":"https://secwatch.observer/filing/0000950170-25-061836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/0000950170-25-061836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017025061836/kura-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:09:35.523196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}